Save the date: 2018 NF Conference in Paris, France

Apr 20, 2017, Posted in Collaborations, NF Conference, Science

Mark your calendar: the 2018 NF Conference will be taking place November 2-6, 2018 at the Maison de la Chimie in Paris, France.  As details become available, they will be posted at

Registration for the 2017 NF Conference is now open - Abstract submission deadline extended to Monday, March 20th

Feb 17, 2017, Posted in NF Conference, Science

Join us June 10-13, 2017 in Washington, DC for the annual NF Conference, a global event attracting more than 300 participants worldwide across a wide range of scientific disciplines, from research and clinical backgrounds, all focused on improving outcomes for patients with neurofibromatosis type 1 (NF1), neurofibromatosis type 2 (NF2) and schwannomatosis.


2016 NF Conference Program Book Now Available

Aug 4, 2016, Posted in NF Conference, Science

The 2016 NF Conference program book is now available.

Children’s Tumor Foundation Hosts World’s Largest Neurofibromatosis Conference June 17-21 in Austin, Texas

The Children's Tumor Foundation (CTF) is hosting the 2016 NF Conference/Forum, the largest worldwide meeting dedicated entirely to neurofibromatosis (NF), a genetic disorder that affects 1 in 3,000 people and causes tumors to grow throughout the body.

Promising Results in Tumor Shrinkage Study Announced at Neurofibromatosis Conference

Over half of patients treated with selumetinib in phase I trial see reduction in plexiform neurofibromas

New York, June 8, 2015 – As hundreds of the world’s leading NF experts convene in Monterey, California for the NF Conference, the largest gathering dedicated to neurofibromatosis (NF), it was announced today that for the first time in the history of the treatment of plexiform neurofibromas (PNs), over 50% of patients saw decreased volume in these inoperable tumors. In a presentation titled “The Promise of MEK: Therapeutics for NF1”, Brigitte C. Widemann, MD, of the National Cancer Institute (NCI), reported that response data in a phase I trial for children and young adults is showing decreases in tumor volume. Anecdotal improvement in function, and reduction in PN related pain and disfigurement has also been observed.

Next Page